Bahadori, H.R. et al., Proc. Am. Soc. Clin. Oncol., 17:477a (1998) AB:1837. |
T.H. Corbett et al., “Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas,” Cancer, 40(5):2660-2680 (1977). |
T.H. Corbett et al., “Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents,” Cancer Treatment Reports, 66(5):1187-1200 (May 1982). |
David L. Emerson et al., “In vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues,” Cancer Research, 55:603-609 (Feb. 1995). |
Isabelle Madelaine et al., “Sequential Modifications of Topoisomerase I Activity in a Camptothecin-Resistant Cell Line Established by Progressive Adaptation,” Biochemical Pharmacology, 45(2):339-348 (1993). |
Abstract: Japio No. 00965715 for JP 57-116015. |
Abstract: Japio No. 00965774 for JP 57-116074. |
Abstract: Japio No. 01293588 for JP 59-5188. |
Abstract: Japio No. 01541290 for JP 60-19790. |
Abstract: Japio No. 02948687 for JP 1-246287. |
Abstract: Japio No. 02952177 for JP 1-249777. |
Abstract: Derwent No. 01984-110813/198418 for JP 59-051289. |
Tomio Furuta and Teruo Yokokura, “Combination Therapy of CPT-11, a Camptothecin Derivative, with Various Antitumor Drugs Against L1210 Leukemia,” Japanese Journal of Cancer and Chemotherapy, 18(3):393-402 (Mar. 1991); English Abstract p. 402. |
M. Ise, C. Sakai, H. Tsujimura, K. Kumagai, T. Takenouchi and T. Takagi, “Sucessful Treatment with CPT-11 and Adriamycin for Hemophagocytic Syndrome Associated with Intravascular Lymphomatosis,” Jpn J. Clin. Hematology39(11):1131-1136; English Abstract p. 1136. |
C. Sakai, T. Saotome, A. Takeshita, C. Nakaseko, K. Kumagai, and T. Takagi, “Irinotecan + Adriamycin QOL,” Jpn. J. Cancer Chemotherapy 26(5):709-714 (1999); Chemical Abstract 115:21789. |